Mexico enlists Moderna to boost mRNA supply for respiratory diseases
The Mexican Government has struck a long-term agreement with Moderna that will see the drugmaker help the country boost its …
Post
-
-
FDA declines to review Moderna’s seasonal flu mRNA vaccine
The US Food and Drug Administration (FDA) has refused to review Moderna’s seasonal influenza jab, mRNA-1010, as the shifting vaccine …
-
Gilead expects 6% of HIV sales growth in 2026, with $800m Yeztugo target
Gilead said it expects sales for its HIV portfolio to increase 6% in 2026 compared to 2025, spearheaded by growth …
-
THX Pharma and Biocodex sign licensing deal for Batten-1 and TX01 drugs
THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 …
-
Insilico and CMS launch drug discovery collaborations for CNS diseases
Insilico Medicine has announced several AI drug discovery collaborations with China Medical System (CMS) across several projects in central nervous …
-
AstraZeneca bets on continued oncology demand for 2026 growth
AstraZeneca expects profits to increase in 2026, as it counts on strong demand for its oncology portfolio continuing despite geopolitical …
-
AbbVie’s $100bn deal aligns drug pricing with domestic manufacturing goals
Under the three-year deal, AbbVie agreed to lower prices on certain Medicaid drugs and expand distribution through the TrumpRx direct-to-patient …
-
RWD and RWE are rewriting how we design and run trials
Traditional randomized controlled trials (RCTs) have long been the gold standard for testing new therapies, but they are increasingly strained …
-
A New Strategic Blueprint: Designing Smarter Early Phase Trials in Oncology
Cancer drugs form one of the most dynamic segments of pharmaceuticals, powered by rising incidence, ageing populations, deeper cancer biology, …
-
By the Numbers: Oncology Trial Activation Timelines and Global Reach
The volume of current activity in the oncology space is enormous. GlobalData’s clinical trial database – a repository of data …
-
REGENXBIO receives FDA response for RGX-121 application
REGENXBIO has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) related to its biologics licence …
-
Takeda and Iambic announce $1.7bn deal to advance small molecule programmes
Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a …
-
Eli Lilly bets on in vivo cell therapy in $2.4bn Orna Therapeutics buyout
Eli Lilly is acquiring in vivo cell therapy-focused biotech, Orna Therapeutics, in an immunology deal worth up to $2.4bn. Through the …
-
Novo sues Hims & Hers despite Wegovy pill offering U-turn
Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and …
-
Robots and pharma logistics: is the future inside a McKesson warehouse?
Across the pharmaceutical sector, governments in major markets are placing increasing pressure on the industry for full visibility and traceability …
